VTECE - V2

Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty	Relationship Identified With:
Charles V. Pollack Jr., MD	Consultant/Advisor: AstraZeneca Pharmaceuticals; Anthos Therapeutics; Milestone Pharmaceuticals; Huyabio; Provepharm US Grant/Research Support: Provepharm US

Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours.
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-24-002-H01-P.)
Learners should only claim credit commensurate with the extent of their participation.

This activity has been supported by an independent educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Name*

First NameLast Name

Email*

example@example.com

I am a:

If Physician, I am primarily a:

If Pharmacist, DOB:*

Date

If Pharmacist, NABP ID#:*

I work primarily in:

I work primarily in the:

Inpatient settingOutpatient settingOther

I engaged with this program via:

After completing this program, my use of DOACs instead of warfarin will:

IncreaseDecreaseStay the same

I would recommend this program and format to my colleagues.

YesNo

I am aware of CE/CME courses available on Twitter from @cardiomet_ce.

TrueFalse

Guidelines recommend DOACs over VKAs for the management of VTE based on data that show all but which of the following?*

a. Fewer deathsb. Fewer PEsc. Fewer DVTsd. Fewer major bleeds

Attestation to Time Spent on Activity:
AcademicCME designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits^TM, 0.50 CNE Contact Hours, or 0.50 CPE Contact Hours (0.05 CEUs) UAN # JA4008190-0000-24-002-H01-P for participation in the full educational activity.

I participated in this activity and claim:*

AMA PRA Category 1 Credits^TMCNE Contact HoursCPE Contact Hours (CEUs)

Date